Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

52.10EUR
7 Dec 2016
Change (% chg)

€-0.10 (-0.19%)
Prev Close
€52.20
Open
€52.70
Day's High
€52.70
Day's Low
€51.55
Volume
108,454
Avg. Vol
74,613
52-wk High
€62.45
52-wk Low
€41.66

DIAS.MI

Chart for DIAS.MI

About

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease,... (more)

Overall

Beta: 0.39
Market Cap(Mil.): €2,867.35
Shares Outstanding(Mil.): 55.95
Dividend: 0.65
Yield (%): 1.27

Financials

  DIAS.MI Industry Sector
P/E (TTM): 25.33 31.03 30.77
EPS (TTM): 2.02 -- --
ROI: 17.28 13.42 15.23
ROE: 19.01 17.11 16.56

BRIEF-Diasorin Q3 net profit rises to EUR 28.7 mln

* Reports Q3 net profit 28.7 million euros ($31.21 million)versus 23.2 million euros a year ago

Nov 10 2016

BRIEF-DiaSorin launches clostridium difficile molecular test

* Launches a molecular test to detect clostridium difficile for markets outside of the United States

Nov 02 2016

BRIEF-DiaSorin and Beckman Coulter form partnership to bring hepatitis and HIV tests to U.S.

* DiaSorin and Beckman Coulter Diagnostics (Beckman Coulter) form strategic partnership to bring Liaison XL hepatitis and HIV products to the United States market

Aug 30 2016

BRIEF-DiaSorin Q2 net profit up 12.0 pct to EUR 29.4 mln

* Q2 net profit 29.4 million euros ($32.73 million), up 12.0 percent year on year

Aug 04 2016

BRIEF-DiaSorin launches test Iam AML1-ETO for screening of acute myeloid leukemia

* Launches Iam AML1-ETO, a test for the molecular screening of acute myeloid leukemia

Jul 14 2016

Earnings vs. Estimates